Thierry Abribat, Amolyt Pharma CEO (via BIOVISION Forum on YouTube)
January 6, 2023 01:37 PM EST
Financing

Amolyt hauls in €130M round to fund PhI­II tri­al of hy­poparathy­roidism drug

Drew Armstrong

Executive Editor

French-Amer­i­can biotech Amolyt Phar­ma has raised a €130 mil­lion ($138 mil­lion) Se­ries C round, plan­ning to use the cash to take its hy­poparathy­roidism drug in­to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump picks vac­cine skep­tic Kennedy to lead HHS, in what would be an up­heaval of US health pol­i­cy

Eu­ro­pean drug reg­u­la­tor re­vers­es opin­ion on Ei­sai and Bio­gen's Alzheimer's drug

Gilead will close Philadel­phia, Seat­tle of­fices as part of job re­duc­tions

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times